A 55-year-old Asian female doctor in a white coat looks directly at the camera with a deep gaze. To her left, an FDA APPROVED logo and text reads 'FDA Approves Taletrectinib for ROS1 Positive NSCLC' in blue and orange, set against a blue background.

FDA Approves Taletrectinib for ROS1-Positive NSCLC – Full Details

On June 11, 2025, the U.S. Food and Drug Administration (FDA) approved taletrectinib (Ibtrozi, Nuvation Bio Inc.), a new kinase inhibitor. FDA approval of taletrectinib for ROS1-positive NSCLC is a significant advancement. This treatment is for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). Meanwhile, this is big news for patients … Continue reading FDA Approves Taletrectinib for ROS1-Positive NSCLC – Full Details

OncologyTube